TrialThe Journal of clinical investigation2014

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

Pierre-Alexandre Bart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.